Intracranial Drug Delivery Devices: A Promising Approach for Future Epilepsy Treatment?

Epilepsy is a prevalent neurological disorder characterized by abnormal neuronal discharges, leading to spontaneous and recurrent seizure attacks. Antiseizure Drugs (ASDs) are the primary treatment, but about 30% of patients develop Drug-Resistant Epilepsy (DRE). An important reason is the inadequate drug concentration within epileptic foci. The brain is protected by the selective blockade of the blood-brain barrier, which not only diminishes the therapeutic efficacy of ASDs but also leads to adverse effects at high doses. Epilepsy surgery may be an alternative. However, the limited indications of surgery, as well as its postoperative efficacy, restrict its wider use. Targeted delivery of ASDs to epileptic foci represents a promising approach. It enables more efficient and precise drug delivery, significantly enhancing therapeutic efficacy while minimizing systemic toxicities and improving safety and quality of life. Our review comprehensively summarizes recent studies on targeted drug delivery devices for epilepsy, including invasive, semi-invasive, and noninvasive approaches, and also explores the potential application of nanoparticles as drug carriers, hoping to provide a novel direction for future epilepsy treatment.

Authors

Institutions

Publication Details

Journal
Current Neuropharmacology
Published
2026-03-16
DOI
https://doi.org/10.2174/011570159x395802251201065343
Primary Topic
Nanoparticle-Based Drug Delivery
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Intracranial Drug Delivery Devices: A Promising Approach for Future Epilepsy Treatment?

Yifei Zheng, Nannan Wang, Fei Cao, Da Xu et al.
Current Neuropharmacology
Nanoparticle-Based Drug Delivery
article

Intracranial Drug Delivery Devices: A Promising Approach for Future Epilepsy Treatment?

Yifei Zheng, Nannan Wang, Fei Cao, Da Xu, Lin-Han Zhang
article en

Abstract

Epilepsy is a prevalent neurological disorder characterized by abnormal neuronal discharges, leading to spontaneous and recurrent seizure attacks. Antiseizure Drugs (ASDs) are the primary treatment, but about 30% of patients develop Drug-Resistant Epilepsy (DRE). An important reason is the inadequate drug concentration within epileptic foci. The brain is protected by the selective blockade of the blood-brain barrier, which not only diminishes the therapeutic efficacy of ASDs but also leads to adverse effects at high doses. Epilepsy surgery may be an alternative. However, the limited indications of surgery, as well as its postoperative efficacy, restrict its wider use. Targeted delivery of ASDs to epileptic foci represents a promising approach. It enables more efficient and precise drug delivery, significantly enhancing therapeutic efficacy while minimizing systemic toxicities and improving safety and quality of life. Our review comprehensively summarizes recent studies on targeted drug delivery devices for epilepsy, including invasive, semi-invasive, and noninvasive approaches, and also explores the potential application of nanoparticles as drug carriers, hoping to provide a novel direction for future epilepsy treatment.

Current NeuropharmacologyVol. 24
Wuhan Union Hospital (CN), Union Hospital (CN)
Good health and well-being
Openalex Percentile: Top 20%
Nanoparticle-Based Drug Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.